Sarepta Wins $115 Million Patent Verdict

 Nippon Shinyaku Co. must pay Sarepta Therapeutics Inc. and the University of Western Australia $115.2 million for patent infringement by its Viltepso drug, a federal jury found Friday.

Jurors awarded the damages as lost profits for US sales of Viltepso that infringe US Patent No. 9,994,851, which Sarepta has exclusively licensed from UWA for the treatment of muscular dystrophies, according to the second-phase verdict issued Friday in the US District Court for the District of Delaware. The jury declined to award Sarepta and UWA a reasonable royalty for infringing US sales that weren’t part of the lost-profits damages.

https://news.bloomberglaw.com/ip-law/nippon-shinyaku-owes-sarepta-115-million-on-gene-therapy-patent